Atria Investments Inc Sells 1,916 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Atria Investments Inc lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,065 shares of the biopharmaceutical company’s stock after selling 1,916 shares during the period. Atria Investments Inc’s holdings in Halozyme Therapeutics were worth $748,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Verdence Capital Advisors LLC raised its holdings in Halozyme Therapeutics by 1.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after buying an additional 252 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares during the period. Fifth Third Bancorp grew its stake in shares of Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 261 shares during the last quarter. Private Advisor Group LLC increased its holdings in Halozyme Therapeutics by 1.8% in the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock valued at $1,191,000 after purchasing an additional 412 shares during the period. Finally, Juncture Wealth Strategies LLC raised its position in Halozyme Therapeutics by 3.6% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 415 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of a number of analyst reports. HC Wainwright upped their price target on Halozyme Therapeutics from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Benchmark reiterated a “buy” rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JMP Securities upped their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 70,000 shares of company stock valued at $4,042,500. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Trading Down 6.7 %

HALO opened at $42.57 on Tuesday. The company has a market cap of $5.42 billion, a P/E ratio of 14.10, a price-to-earnings-growth ratio of 0.42 and a beta of 1.29. The company has a fifty day moving average price of $56.04 and a two-hundred day moving average price of $53.48. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.